Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): June 17, 2020





(Exact name of registrant as specified in Charter)


Washington   001-35521   26-2056298

(State or other jurisdiction of

incorporation or organization)

  (Commission File No.)   (IRS Employee Identification No.)



12870 Interurban Avenue South

Seattle, Washington 98168

(Address of Principal Executive Offices)



(Issuer Telephone number)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2 below).


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).


¨Pre-commencement communications pursuant to Rule 13e-(c) under the Exchange Act (17 CFR 240.13(e)-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   CLIR   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨






Item 3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard: Transfer of Listing


On June 18, 2020, ClearSign Technologies Corporation (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, due to the decision of Dr. Lon E. Bell not to stand for election as a director at the Company’s 2020 annual meeting of shareholders (the “Annual Meeting”), which was held on June 17, 2020, the Company no longer meets the requirements of Listing Rule 5605(b)(1) (Majority Independent Board) and Listing Rule 5605(c)(2) (Audit Committee Composition). However, consistent with Listing Rules 5605(b)(1)(A) and 5605(c)(4), Nasdaq has provided the Company a cure period in order to regain compliance as follows:


·until the earlier of the Company’s next annual shareholders’ meeting or June 17, 2021; or


·if the next annual shareholders’ meeting is held before December 14, 2020, then the Company must evidence compliance no later than December 14, 2020.


The Company intends to undertake a search for an independent director and to appoint that person to the Board of Directors within the cure period.


Item 5.07Submission of Matters to a Vote of Security Holders.


As noted above, on June 17, 2020, the Company held its Annual Meeting. A total of 21,882,468 shares of common stock, constituting a quorum, were represented in person or by proxies at the Annual Meeting. The following are the voting results on each matter submitted to the shareholders. The proposals below are described in detail in the Company’s proxy statement, which was filed with the Securities and Exchange Commission on April 27, 2020.


Proposal 1. Each of the following nominees was elected to serve as a director until the election and qualification of his or her successor.


Nominee Name  For  Withheld  Broker Non-Votes
Robert T. Hoffman  9,604,722  1,813,475  10,464,271
Susanne L. Meline  11,364,164  54,033  10,464,271
Bruce A. Pate  11,349,672  68,525  10,464,271
Colin James Deller  9,596,470  1,821,727  10,464,271





Proposal 2. The shareholders approved, on an advisory basis, Gumbiner Savett Inc. as the Company’s independent registered public accounting firm for the year ended December 31, 2020.


For  Against  Abstentions  Broker Non-Votes
21,845,989  29,731  6,748  0


Proposal 3. The shareholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers.


For  Against  Abstentions  Broker Non-Votes
10,974,954  398,439  44,804  10,464,271


Proposal 4. The shareholders approved one or more adjournments of the Annual Meeting to a later date or dates to solicit additional proxies in the absence of a quorum.


For  Against  Abstentions  Broker Non-Votes
21,052,999  718,197  111,272  0




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: June 22, 2020


  By:  /s/ Brian Fike 
    Brian G Fike 
    Chief Financial Officer